Fluoxetine effects on cerebral glucose metabolism.
In a counterbalanced, double-blind, placebo-controlled trial, 40 mg of fluoxetine was administered to four healthy adult volunteers (three men, one woman; age range 20-39 years), 90 min before injection of 6-7.5 mCi of [18F]-2-deoxyglucose to measure cerebral metabolic rate of glucose (CMRglu). Subjects were engaged in a visual monitoring task shortly before and during scanning with a PETT-VI tomograph. Global CMRglu did not differ when placebo (8.93 +/- 0.96 mg 100 g-1 min-1) was compared to fluoxetine (8.22 +/- 0.86 mg 100 g-1 min-1; paired t-test = 0.82, df = 3, p < 0.48). However, statistical parametric mapping of differences in CMRglu between placebo and fluoxetine conditions revealed regional effects of fluoxetine shown by decreased metabolism in the amygdaloid complex, hippocampal formation and ventral striatum, and by increased metabolism centered in the right superior parietal lobe (Brodmann area 7). Parametric mapping for use in PET studies of glucose metabolism represents a significant new tool for studying drug effects in humans.
Cook
E H
EH
Department of Psychaitry, University of Chicago, IL 60637.
Metz
J
J
Leventhal
B L
BL
Lebovitz
M
M
Nathan
M
M
Semerdjian
S A
SA
Brown
T
T
Cooper
M D
MD
D000328:Adult; D001923:Brain Chemistry / Q000187:drug effects*; D003847:Deoxyglucose / Q000031:analogs & derivatives; D004311:Double-Blind Method; D005260:Female; D019788:Fluorodeoxyglucose F18; D005473:Fluoxetine / Q000494:pharmacology*; D005947:Glucose / Q000378:metabolism*; D006801:Humans; D007091:Image Processing, Computer-Assisted; D007700:Kinetics; D008297:Male; D014055:Tomography, Emission-Computed
D005473:Fluoxetine; D019788:Fluorodeoxyglucose F18; D003847:Deoxyglucose; D005947:Glucose